Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




High Sensitivity Blood Test Aids Emergency Diagnosis of Heart Conditions

By LabMedica International staff writers
Posted on 29 Nov 2023

Troponin, a protein released into the bloodstream during heart attacks or other heart injuries, has long been a focal point in medical diagnostics. More...

Traditionally, various troponin blood tests have aided doctors in diagnosing heart conditions, especially in individuals experiencing chest pain and similar symptoms. Now, researchers have discovered a new method of measuring troponin levels, offering the potential to reduce future heart attacks in high-risk patients by 10% over five years. This advanced test is distinguished by its heightened accuracy in detecting even minimal troponin levels in the bloodstream, surpassing the capabilities of older tests.

Researchers at the University of Edinburgh (Scotland, UK) conducted an extensive study to evaluate the effectiveness of this innovative test. They analyzed health data from nearly 50,000 individuals with a suspected heart attack who visited ten emergency departments across Scotland between 2013 and 2016. Using general health records, the team tracked these individuals over five years. The new test identified over 10,000 patients with elevated troponin levels, indicative of heart injury. Notably, this high-sensitivity test detected subtle warning signs, identifying about 20% of these cases, which would have been missed by traditional tests.

The most significant impact of the test was observed in patients with heart muscle injuries caused by other cardiac conditions, such as heart failure, valve issues, and arrhythmias. Analysis showed that these patients experienced nearly a 10% reduction in subsequent hospital admissions and mortality over the following five years when tested with the new method, compared to those who underwent the older, less sensitive testing. This advancement in detecting heart injuries, particularly in cases that might have previously been overlooked, could enable more patients to receive specialized cardiac care, potentially preventing more severe health incidents in the future.

“In the past, clinicians could have been falsely reassured by the results of the less sensitive troponin test, discharging patients that appeared to not have heart disease,” said Dr Ken Lee, Clinical Lecturer in Cardiology at the University of Edinburgh. “This new high sensitivity test is the tool they needed, prompting them to look deeper and helping them to identify and treat both heart attacks and less obvious heart problems. In our trial, introducing this test led to an impressive reduction in the number of future heart attacks and deaths seen in this at-risk group.”

“Medical professionals in emergency departments need the most efficient and accurate tools to look after people,” added Professor Sir Nilesh Samani, Medical Director at the British Heart Foundation, which funded the study. “This particularly applies to those who arrive with a suspected heart attack. Such a time-sensitive and life-threatening condition requires the very best diagnostic tests. It is very encouraging to see that the new test trialed here is better at predicting long-term outcomes for these patients, whether they had a heart attack or a different kind of heart injury. This can lead to improved care for such patients.”

Related Links:
University of Edinburgh 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.